4.0
Jul 14, 2026
Current employee, more than 3 years
Cambridge, MA
Recommend
CEO approval
Business Outlook
Pros
Good pay; in most cases reasonable hybrid expectations Proud to see pursuit of rare disease treatments Trying to improve our structures & ways of working
Cons
Multi-year restructuring & cost-cutting ongoing At times can feel like the company wants to be big pharma but doesn't know how Remote opportunities seem to be decreasing